Director Simon Farrell awarded 30,500 options at Serina (SER)
Rhea-AI Filing Summary
Serina Therapeutics, Inc. reported that director Simon Farrell received a grant of stock options covering 30,500 shares of common stock. The options have an exercise price of $2.1700 per share, expire on 2036-07-22, and vest in substantially equal yearly installments over three years beginning on the first anniversary of the grant date, subject to his continued service. Following this grant, Farrell holds 30,500 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Simon Farrell
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 30,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,500 shares (Direct)
Footnotes (1)
- F1. The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Key Figures
Stock options granted: 30,500 options
Exercise price: $2.1700 per share
Underlying common shares: 30,500 shares
+2 more
5 metrics
Stock options granted
30,500 options
Grant to director Simon Farrell on 2026-07-22
Exercise price
$2.1700 per share
Exercise price of the reported stock option grant
Underlying common shares
30,500 shares
Common Stock underlying the granted stock options
Options expiration date
2036-07-22
Expiration date of the granted stock options
Vesting period
3 years
Options fully vested on the third anniversary of the grant date
Key Terms
Stock Option (right to buy), exercise price, vesting, underlying security
4 terms
Stock Option (right to buy) financial
"Security title reported as Stock Option (right to buy)"
exercise price financial
"Conversion or exercise price reported as 2.1700 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock options vest in substantially equal yearly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"Underlying security title identified as Common Stock"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Serina Therapeutics (SER) report for director Simon Farrell?
Serina Therapeutics reported a grant of 30,500 stock options to director Simon Farrell. The options let him buy common shares at $2.17 each, expiring on July 22, 2036, and vest in equal annual installments over three years of continued service.
What is the exercise price of Simon Farrell’s new options at Serina Therapeutics (SER)?
The granted stock options have an exercise price of $2.1700 per share. This is the fixed price at which Farrell may purchase Serina Therapeutics common stock upon exercise of the options, subject to the vesting schedule and other grant conditions.
How do the 30,500 Serina Therapeutics (SER) stock options granted to Simon Farrell vest?
The 30,500 stock options vest in substantially equal yearly installments. Vesting starts on the first anniversary of the grant date and the options become fully vested on the third anniversary, contingent on Farrell’s continued service with Serina Therapeutics.
When do Simon Farrell’s Serina Therapeutics (SER) stock options expire?
The stock options granted to Simon Farrell expire on July 22, 2036. After that expiration date, any unexercised options will lapse, meaning they can no longer be used to purchase Serina Therapeutics common stock under this grant.
What are Simon Farrell’s reported option holdings in Serina Therapeutics (SER) after this grant?
After the reported transaction, Simon Farrell directly holds 30,500 stock options. These options relate to an equal number of underlying Serina Therapeutics common shares, subject to the grant’s vesting schedule and the stated exercise price and expiration date.